|
|
National Jewish Medical and Research Center
Research Funding
(listed alphabetically by Principal Investigator or by Section faculty member involved)
2005
A Multicenter, Randomized, Vehicle-Controlled Clinical Study to Examine the Efficacy and Safety of Atopiclair in the Management of Mild to Moderate Atopic Dermatitis in Adults
Principal Investigator: Mark Boguniewicz, MD
Source: Sinclair Pharmaceuticals
Term: 2004-present
A Six-Week Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Elidel Cream 1% in Patients with Mild to Moderate Chronic Hand Dermatitis, Followed by a Six-Week Open-Label Phase to Assess the Safety of Elidel Cream 1%
Principal Investigator: Mark Boguniewicz, MD
Source: Novartis Pharmaceuticals
Term: 2004-present
A Two-Stage Randomized, Open-Label, Parallel Group, Phase III Multicenter, 7-Month Study to Assess the Efficacy and Safety of Symbicort pMDI Administered Either as Fixed or as an Adjustable Regimen vs. a Fixed Regimen of Advair in Subjects 12 Years of Age or Older with Asthma
Principal Investigator: Mark Boguniewicz, MD
Source: AstraZeneca Pharmaceuticals
Term: 2003-2005
An Investigation of the Safety and Efficacy of Elidel 1% Cream in Atopic Disease Modification, Assessed in a Three-Year Randomized, Double-Blind Vehicle-Controlled Phase to Evaluate the Effects of Atopic Dermatitis in Infants, and a Two-Three-Year Open-Label Phase to Evaluate the Effect of Early Intervention vs. Delayed Intervention with Elidel on the Incidence of Asthma in Children
Principal Investigator: Mark Boguniewicz, MD
Source: Novartis Pharmaceuticals
Term: 2003-present
An Investigation of the Safety and Efficacy of Elidel 1% Cream in an Exploratory, Double-Blind, Randomized, Vehicle-Controlled, Paired Study to Evaluate the Efficacy and Safety of Concomitant Use of Pimecrolimus Cream 1% and Fluticasone Propionate Cream 0.05% in Patients with Severe Lesions of Atopic Dermatitis
Principal Investigator: Mark Boguniewicz, MD
Source: Novartis Pharmaceuticals
Term: 2004-present
Immune Response to Varicella Vaccination in Subjects with Atopic Dermatitis Compared to Nonatopic Controls
Principal Investigator: Mark Boguniewicz, MD
Source: National Institute of Allergy and Infectious Diseases, Atopic Dermatitis and Vaccinia Network Clinical Studies Consortium
Amount: $20,723,556
Term: 2005-2009
Cell Culture Core: Ether Lipids, Eicosanoids and Lung Cell Pathophysiology
Co-Investigator: Donna L. Bratton, MD
Program Director: Peter M. Henson, PhD
Source: National Institutes of Health - PO1 HL34303
Amount: $117,894/yr
Term: 2000-2005
Defective Phosphatidylserine Exposure in Eutrophil Apoptosis in Chronic Granulomatous Disease
Principal Investigator: Donna L. Bratton, MD
Source: National Institutes of Health - R01 AI058228
Amount: $175,000/yr
Term: 2003-2007
Phospholipid Signaling from Apoptotic Cells, Project 3
Program Project Grant: Ether Lipids, Eicosanoids, and Lung Cell Pathophysiology
Program Director: Christina C. Leslie, PhD
Principal Investigator: Donna L. Bratton, MD
Source: National Institutes of Health - HL34303
Amount: $251,822/yr
Term: 2005-2010
Age-Dependent Increases in Airway Responsiveness by RSV
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - R01 HL6 1005
Amount: $198,071/yr
Term: 1999-2008
Airway Function: The Role of T-Cells
Principal Investigator: Willi Born, PhD
Co-Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - 1U01 HL65899-01
Amount: $203,656/yr
Term: 2000-2009
Inflammation, Airway Reactivity and Asthma
Project 2: Role of T Lymphocytes in Airway Hyperresponsiveness
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Azzeddine Dakhama, PhD
Source: National Institutes of Health - HL-36577
Amount: $243,791
Term: 2001-2006
Inflammation, Airway Reactivity and Asthma
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - HL36577
Term: 2001-2006
- Mechanisms in Steroid-Resistant Asthma
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Donald Y. M. Leung, MD, PhD
Amount: $246,061/yr
- Role of T Lymphocytes in Airway Hyperresponsiveness
Principal Investigator: Erwin W. Gelfand, MD
Amount: $258,638/yr
- Eosinophil, Eicosanoid Biosynthesis and Metabolism
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Robert C. Murphy, PhD
Amount: $197,180/yr
Inhalation of Particulate Matter Alters the Allergic Airway Response to Inhaled Allergen
Principal Investigator: Erwin W. Gelfand, MD
Source: Environmental Protection Agency - R825702
Amount: $235,043/yr
Term: 1997-2008
Pharmacogenetics Research Network and Database
Principal Investigator: Scott Weiss, MD
Principal Investigator (Denver site): Erwin W. Gelfand, MD
Source: National Institutes of Health - 1U01 HL65899-01
Amount: $214,337/yr
Term: 2000-2005
Training Program in Pediatric Immunology
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - T32 A107365
Amount: $158,839/yr
Term: 1990-2005
Institutional Review Board Assessment and Education Project
Principal Investigator: Richard B. Johnston, Jr., MD
Source: National Institutes of Health, National Center for Research Resources
Amount: $150,000
Term: 2002-2005
Neuroimmune Interactions in Developing Airways
Principal Investigator: Gary L. Larsen, MD
Co-Investigator: Azzeddine Dakhama, PhD
Source: National Institutes of Health - RO1 HL-67818
Amount: $225,000
Term: 2002-2006
The Atopic Dermatitis Vaccinia Network: Animal Studies Consortium
Principal Investigator: Raif Geha, MD, PhD
Co-Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Institutes of Allergy and Infectious Diseases - HHSN266200400030C, ADB Contract #N01-AI-40030
Amount: $10,031,776
Term: 2004-2009
The Atopic Dermatitis Vaccinia Network: Clinical Studies Consortium
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Institutes of Allergy and Infectious Diseases - HHSN26620040029C, ADB Contract #N01-AI-40029
Amount: $20,723,556
Term: 2004-2009
Effect of Pimecrolimus on T-Cell Responses in Atopic March
Principal Investigators: Jonathan M. Spergel, MD - Children's Hospital of Philadelphia (CHOP), and Hugh A. Sampson, MD - Mt. Sinai
Denver Site Leader: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Institutes of Allergy and Infectious Diseases - 1R01AI62698
Amount: $708,721
Term: 2005-2009
Immunology of Peanut Allergy and Its Treatment: A Prototype
Principal Investigator: Hugh A. Sampson, MD - Mt. Sinai
Denver Site Leader: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Institutes of Allergy and Infectious Diseases - 1 U19 AI066738-01
Amount: $16,430,158
Term: 2005
Immunomodulation of Vaccinia-Induced Antimicrobial Peptides
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases - 5 R21 AR051634-02
Amount: $156,600
Term: 2004-2006
Pediatric Clinical Translational Research Center
Principal Investigator: Principal Investigator: Richard Krugman, MD
Associate Program Director: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Center for Research Resources - 3M01RR00051
Amount: $8,500,000
Term: 2001-2006
Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus
Principal Investigator: Donald Y. M. Leung, MD, PhD
Co-Investigator: Mark Boguniewicz, MD
Source: National Institute of Allergy and Infectious Disease, Atopic Dermatitis and Vaccinia Network Clinical Studies Consortium
Amount: $20,723,556
Term: 2005-2009
Role of Bacterial Toxins in Human Skin Diseases
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases - 1RO1 AR41256
Amount: $1,125,000
Term: 2005-2010
Role of Bacterial Toxins in Human Skin Diseases
Principal Investigator: Donald Y. M. Leung, MD, PhD
Co-Investigator: Mark Boguniewicz, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - 5 R01 AR-41256
Amount: $1,544,400
Term: 2005-2010
Role of IL-31 in Atopic Dermatitis
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: Zymogenetics
Amount: $102,000
Term: 2004-2005
Role of Xolair in Peanut Allergy
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: Genentech, Inc. - Protocol Q2788G
Amount: $155,414
Term: 2004-2006
Endotoxin and Asthma Prevention in Young Children
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute
Amount: $577,182/yr
Term: 2001-2006
Immune Pathogenesis and Prevention of Asthma in Young Children
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, Pediatric Clinical Translational Research Center - M01 RR00051, NJ137
Amount: $125,000/yr
Term: 1998-2005
Immunology of Peanut Allergy and its Treatment: A Prototype (IPAT)
Principal Investigator: Hugh Sampson, MD
Co-Investigator: Andrew H. Liu, MD
Amount: $16,430,158
Source: National Institutes of Health
Term: 2005-2010
Inner City Asthma Consortium
Principal Investigator: William Busse, MD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health
Term: 2002-2008
Prevention of Chronic Asthma: Age 7 Follow-up
Principal Investigator: Mary Klinnert, PhD
Co-Investigators: Andrew H. Liu, MD, and Bruce Bender, PhD
Source: National Institutes of Health - R18 AI41137
Amount: $175,000
Term: 2002-2006
Prevention of Chronic Asthma in Young Children
Principal Investigator: Mary D. Klinnert, MD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Institutes of Allergy and Infectious Diseases
Term: 1997-2006
Study of Allergen, Genetics and Endotoxin (SAGE)
Principal Investigator: Lee Newman, MD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health
Amount: $225,000
Term: 2005-2010
Air Pollution Health Effects: A Source-Oriented Approach
Principal Investigator: Sverre Vedal, MD
Co-Investigator: Nathan Rabinovitch, MD
Source: National Institutes of Health - R01ES012197
Amount: $1,800,000
Term: 2004-2009
Air Pollution, LTE4, and Decreased Asthma Control: Prevention with Montelukast
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Nathan Rabinovitch, MD
Source: Merck - 31359
Amount: $120,000
Term: 2005-2006
Health Effects of Environmental Tobacco Smoke (ETS) in Urban Poor Minority Children with Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Colorado Tobacco Research Project
Amount: $250,000/yr
Term: 2002-2005
Health Effects of Personal Exposure to Particulate in Children with Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Environmental Protection Agency
Amount: $202,211/yr
Term: 1999-2005
Impact of Poor Air Quality on Severity of Childhood Asthma
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Nathan Rabinovitch, MD
Source: Thrasher Research Fund - 02816
Amount: $120,000/yr
Term: 2002-2006
Personal Exposure to Particulate Air Pollution in Childhood Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Environmental Protection Agency - R825702
Amount: $150,000/yr
Term: 1999-present
Asthma Clinical Research Network
Co-Investigators: Stanley J. Szefler, MD, and Richard Martin, MD
Source: National Heart, Lung and Blood Institute - HL 51834
Amount: $2,500,000
Term: 2003-2008
Childhood Asthma Management Program Continuation Study
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Ronina A. Covar, MD
Source: National Institutes of Health
Amount: $809,822
Term: 2003-2007
Childhood Asthma Management Program Continuation Study/Phase 2
Principal Investigator: Stanley J. Szefler, MD
Source: National Heart, Lung and Blood Institute
Amount: $809,822
Term: 2004-2008
Childhood Asthma Research and Education Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Ronina A. Covar, MD
Source: National Institutes of Health
Amount: $8,317,722
Term: 1999-2009
Childhood Asthma Research and Education Network
Principal Investigator: Stanley J. Szefler, MD
Source: National Heart Lung and Blood Institute
Amount: $3,500,000
Term: 2004-2009
Childhood Asthma Research and Education (CARE) Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Marzena E. Krawiec, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - U10-HL64288
Amount: $883,010
Term: 2004-2009
Inner City Asthma Consortium
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Ronina A. Covar, MD
Source: National Institutes of Allergy and Infectious Disease
Amount: $996,177
Term: 2002-2006
Inner City Asthma Consortium
Principal Investigator (Denver site): Stanley J. Szefler, MD
Source: National Institutes of Allergy and Infectious Diseases
Amount: $6,000,000
Term: 2002-2008
Evaluation of a Nutritional Formula for Asthma Intervention in Children
Principal Investigator: Stanley J. Szefler, MD
Source: Ross Pharmaceuticals
Amount: $1,100,000
Term: 2004-2006
Biochemical Basis of Ozone Toxicity
Principal Investigator: Carl W. White, MD
Source: Environmental Protection Agency
Amount: $90,000/yr
Term: 2004-2005
Cigarette Smoke, Oxidants and S-Adenosylmethionine
Principal Investigator: Carl W. White, MD
Source: Colorado Tobacco Research Program
Amount: $468,253
Term: 2003-2005
Hypoxia-Inducible Factors in Bronchopulmonary Dysplasia
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - 5 U01 HL056263
Amount: $225,000/yr
Term: 2003-2007
Lung Epithelial Cell Survival Signaling in Ozone in Cystic Fibrosis and Normals
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - 1 RO1 ES014448-01
Amount: $213,750/yr
Term: 2005-2010
Mechanisms of Particulate Toxicity - Ozone Exposure Core
Overall Principal Investigator: Robert J. Mason, MD
Project Principal Investigator: Carl W. White, MD
Source: Environmental Protection Agency
Amount: $83,840
Term: 2005-2006
Mechanisms of Sulfur Mustard Toxicity to Lung
Principal Investigator: Brian Day, PhD
Co-Investigator: Carl W. White, MD
Source: National Institutes of Health Supplement
Amount: $45,000/yr
Term: 2005-2006
2003-2004
A Multicenter, Randomized, Vehicle-Controlled Clinical Study to Examine the Efficacy and Safety of Atopiclair in the Management of Mild to Moderate Atopic Dermatitis in Adults
Principal Investigator: Mark Boguniewicz, MD
Source: Sinclair Pharmaceuticals
Term: 2004-present
A Phase III, Randomized, Double-Blind Study Comparing Twice Daily FK506 Cream 0.03% vs. Cream Vehicle in the Treatment of Atopic Dermatitis in Pediatric Patients
Principal Investigator: Mark Boguniewicz, MD
Source: Fujisawa USA, Inc.
Term: 2003-2004
A Six-Week Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Elidel Cream 1% in Patients with Mild to Moderate Chronic Hand Dermatitis, Followed by a Six-Week Open-Label Phase to Assess the Safety of Elidel Cream 1%
Principal Investigator: Mark Boguniewicz, MD
Source: Novartis Pharmaceuticals
Term: 2004-present
A Two-Stage Randomized, Open-Label, Parallel Group, Phase III Multicenter, 7-Month Study to Assess the Efficacy and Safety of Symbicort pMDI Administered Either as Fixed or as an Adjustable Regimen vs. a Fixed Regimen of Advair in Subjects 12 Years of Age or Older with Asthma
Principal Investigator: Mark Boguniewicz, MD
Source: AstraZeneca Pharmaceuticals
Term: 2003-2005
An Investigation of the Safety and Efficacy of Elidel 1% Cream in Atopic Disease Modification, Assessed in a Three-Year Randomized, Double-Blind Vehicle-Controlled Phase to Evaluate the Effects of Atopic Dermatitis in Infants, and a Two-Three-Year Open-Label Phase to Evaluate the Effect of Early Intervention vs. Delayed Intervention with Elidel on the Incidence of Asthma in Children
Principal Investigator: Mark Boguniewicz, MD
Source: Novartis Pharmaceuticals
Term: 2003-present
An Investigation of the Safety and Efficacy of Elidel 1% Cream in an Exploratory, Double-Blind, Randomized, Vehicle-Controlled, Paired Study to Evaluate the Efficacy and Safety of Concomitant Use of Pimecrolimus Cream 1% and Fluticasone Propionate Cream 0.05% in Patients with Severe Lesions of Atopic Dermatitis
Principal Investigator: Mark Boguniewicz, MD
Source: Novartis Pharmaceuticals
Term: 2004-present
The Role of IL-31 in Atopic Dermatitis
Principal Investigator: Mark Boguniewicz, MD
Source: ZymoGenetics
Amount: $102,000
Term: 2004-2005
Regulation of Membrane Phospholipid Distribution and Mediator Translocation by Scramblase: Ether Lipids, Eicosanoids and Lung Cell Pathophysiology (Project 4)
Principal Investigator: Donna L. Bratton, MD
Program Director: Peter M. Henson, PhD
Source: National Institutes of Health - PO1 HL34303
Amount: $214,854/yr
Term: 2000-2005
Defective Phosphatidylserine Exposure in Eutrophil Apoptosis in Chronic Granulomatous Disease
Principal Investigator: Donna L. Bratton, MD
Source: National Institutes of Health - R01 AI058228
Amount: $175,000/yr
Term: 2003-2007
Cell Culture Core: Ether Lipids, Eicosanoids and Lung Cell Pathophysiology
Co-Investigator: Donna L. Bratton, MD
Program Director: Peter M. Henson, PhD
Source: National Institutes of Health - PO1 HL34303
Amount: $117,894/yr
Term: 2000-2005
Defective Phosphatidylserine Exposure During Neutrophil Apoptosis in Chronic Granulomatous Disease Inhibits Phagocytic Recognition and Engulfment and Results in Enhanced Inflammation
Principal Investigator: Donna L. Bratton, MD
Source: Immune Deficiency Foundation
Amount: $47,000
Term: 2003-2004
Inflammation, Airways Reactivity and Asthma
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - HL-36577
Term: 2001-2006
- Mechanisms in Steroid-Resistant Asthma
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Donald Y. M. Leung, MD, PhD
Amount: $238,893/yr
- Role of T Lymphocytes in Airway Hyperresponsiveness
Principal Investigator: Erwin W. Gelfand, MD
Amount: $251,104/yr
- Eosinophil, Eicosanoid Biosynthesis and Metabolism
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Robert C. Murphy, PhD
Amount: $191,437/yr
Inhalation of Particulate Matter Alters the Allergic Airway Response to Inhaled Allergen
Principal Investigator: Erwin W. Gelfand, MD
Source: Environmental Protection Agency - R825702
Amount: $235,043/yr
Term: 1997-2004
Regulation of Mast Cell Cytokine Production
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - R01 AL 42246
Amount: $225,000/yr
Term: 1998-2004
Pharmacogenetics Research Network and Database
Principal Investigator: Scott Weiss, MD
Principal Investigator: Erwin W. Gelfand, MD (Denver site)
Source: National Institutes of Health - 1U01 HL65899-01
Amount: $214,337/yr
Term: 2000-2005
Regulation of Airway Function: The Role of T-Cells
Principal Investigator: Willi Born, PhD
Co-Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - 1U01 HL65899-01
Amount: $203,656/yr
Term: 2000-2005
Age-Dependent Increases in Airway Responsiveness by RSV
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Azzeddine Dakhama, PhD
Source: National Institutes of Health - RO1 HL-61005
Amount: $198,071/yr
Term: 1999-2009
Training Program in Pediatric Immunology
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - T32 A107365
Amount: $158,839/yr
Term: 1990-2005
Institutional Review Board Assessment and Education Project
Principal Investigator: Richard B. Johnston, Jr., MD
Source: National Institutes of Health, National Center for Research Resources
Amount: $150,000
Term: 2002-2005
Neuroimmune Interactions in Developing Airways
Principal Investigator: Gary L. Larsen, MD
Co-Investigator: Azzeddine Dakhama, PhD
Source: National Institutes of Health - RO1 HL-67818
Amount: $225,000
Term: 2002-2006
General Clinical Research Center
Principal Investigator: Richard D. Krugman, MD
Co-Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - 5M1RR00052
Amount: $893,938
Term: 2001-2006
Pathogenesis and Etiology of Kawasaki Syndrome
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - 5 R01 HL37260-12
Amount: $785,421
Term: 1999-2004
Role of Bacterial Toxins in Human Skin Diseases
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - 5 R01 AR-41256
Amount: $141,000/yr
Term: 1992-2005
Endotoxin and Asthma Prevention in Young Children
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - K23 HL04272
Amount: $577,182/yr
Term: 2001-2006
Exhaled Breath Condensates Protocol
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Institute of Allergic and Infectious Diseases - N01 AI25946
Amount: $240,725/yr
Term: 2003-2004
Immune Pathogenesis and Prevention of Asthma in Young Children
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, General Clinical Research Center - M01 RR00051, NJ137
Amount: $125,000/yr
Term: 1998-2005
Endotoxin and Asthma Prevention in Young Children
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Institute of Heart, Lung, and Blood Institute - K23-HL-04272-01A1
Amount: $122,418/yr
Term: 2003-2004
Prevention of Chronic Asthma in Young Children
Principal Investigator: Mary D. Klinnert, PhD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Institute of Allergic and Infectious Diseases - R18 AL41137
Term: 1997-2005
Health Effects of Environmental Tobacco Smoke (ETS) in Urban Poor Minority Children with Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Colorado Tobacco Research Project
Amount: $250,000/yr
Term: 2002-2005
Impact of Poor Air Quality on Severity of Childhood Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Thrasher Research Fund
Amount: $250,000/yr
Term: 2002-2005
Personal Exposure to Particulate Air Pollution in Childhood Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Environmental Protection Agency
Amount: $210,000/yr
Term: 2002-2006
Health Effects of Personal Exposure to Particulate in Children with Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Environmental Protection Agency
Amount: $202,211/yr
Term: 1999-2005
Childhood Asthma Research and Education Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Ronina A. Covar, MD
Source: National Heart, Lung and Blood Institute - HL64288
Amount: $600,000/yr
Term: 1999-2004
Asthma Clinical Research Network
Principal Investigator: Richard Martin, MD
Co-Investigator: Stanley J. Szefler, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - HL 51834
Amount: $600,000/yr
Term: 2003-2008
Cockroach Allergen Extract Standardization Study
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Institute of Allergic and Infectious Diseases - N01 AI25946
Amount: $322,000/yr
Term: 2003-2004
Inner City Asthma Consortium
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Ronina A. Covar, MD
Source: National Institutes of Health, National Institute of Allergy and Infectious Diseases - N01 AI25946
Amount: $300,000/yr
Term: 2002-2008
Pediatric Pharmacology Research Unit Network
Principal Investigator: Stanley J. Szefler, MD
Source: National Institutes of Health, National Institute of Child Health and Human
Development - HD37237
Amount: $272,000/yr
Term: 1999-2004
Inner City Asthma Consortium
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Institute of Allergic and Infectious Diseases - N01 AI25946
Amount: $158,000
Term: 2003-2004
Childhood Asthma Management Program
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Ronina A. Covar, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - N01 HL16048
Amount: $132,627/yr
Term: 1991-2004
Cigarette Smoke, Oxidants and S-Adenosylmethionine
Principal Investigator: Carl W. White, MD
Source: Colorado Tobacco Research Program
Amount: $468,253
Term: 2003-2005
Hypoxia-Inducible Factors in Bronchopulmonary Dysplasia
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute
Amount: $230,831/yr
Term: 2003-2007
Biochemical Basis of Ozone Toxicity
Principal Investigator: Carl W. White, MD
Source: Environmental Protection Agency
Amount: $90,000/yr
Term: 2004-2005
2001-2002
Academic Training in Pediatric Pulmonary Diseases
Principal Investigator: Steven H. Abman, MD
Co-Investigator: Gary L. Larsen, MD
Source: National Institutes of Health - HL07670
Amount: $321,185
Term: 1988-2004
Determinants of Early Pancreatic Injury in Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Co-Investigator: James F. Jones, MD
Source: National Institutes of Health
Amount: $77,101
Term: 2002-2003
Pediatric Environmental Health Specialty Unit: EPA Region VIII
Principal Investigators: Mark E. Anderson, MD, and Richard C. Dart, MD
Co-Investigators: Andrew H. Liu, MD, Cecile Rose, MD, and Gregory Bogdan, PhD, MD
Source: Academic Occupational and Environmental Health Clinics
Amount: $128,000/yr
Term: 2001-2004
Regulation of Airway Function: The Role of T-Cells
Principal Investigator: Willi Born, PhD
Co-Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - 1U01 HL65899-01
Amount: $200,000/yr
Term: 2000-2005
C.L.C. Kramer Foundation Scientist in Pediatric Medicine
Endowed Chair: Donna L. Bratton, MD
Source: National Jewish Medical and Research Center
Amount: $5,000/yr
Term: 2000-2003
Defective Phosphatidylserine Exposure During Neutrophil Apoptosis in Chronic Granulomatous Disease Inhibits Phagocytic Recognition and Engulfment and Results in Enhanced Inflammation
Principal Investigator: Donna L. Bratton, MD
Source: Immune Deficiency Foundation
Amount: $94,000
Term: 2003-2004
Ether Lipids, Eicosanoids and Lung Cell Pathophysiology. Cell Culture Core
Co-Investigator: Donna L. Bratton, MD
Source: National Institutes of Health - 1R01 HL60980
Amount: $572,811/yr
Term: 2002-2005
Ether Lipids, Eicosanoids and Lung Cell Pathophysiology. Project 4: Transbilayer Movement of Phospholipids in Membranes
Principal Investigator: Donna L. Bratton, MD
Source: National Institutes of Health - PO1 HL34303
Amount: $1,028,999
Term: 2000-2005
Pathogenesis of Pediatric Chronic Sinusitis
Principal Investigator: Kenny Chan, MD
Co-Investigators: Andrew H. Liu, MD, and Mark Abzug, MD
Source: Pediatric General Clinical Research Center
Term: 1998-2001
Inflammation, Airways Reactivity and Asthma
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - HL36577
Amount: $956,029
Term: 2001-2002
- Mechanisms in Steroid-Resistant Asthma - Project 1
Project Leader: Donald Y. M. Leung, MD, PhD
Amount: $225,180/yr
- Role of T Lymphocytes in Airway Hyperresponsiveness - Project 2
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Gary L. Larsen, MD
Amount: $236,691/yr
- Eosinophil, Eicosanoid Biosynthesis and Metabolism - Project 4
Principal Investigator: Robert C. Murphy, PhD
Amount: $180,449/yr
- Morphology Core
Core Director: Gary L. Larsen, MD
Amount: $105,487/yr
- Administrative Core A
Principal Investigator: Erwin W. Gelfand, MD
Amount: $83,584/yr
- Clinical Core C
Principal Investigator: Richard J. Martin, MD
Amount: $124,639/yr
Inhalation of Particulate Matter Alters the Allergic Airway Response to Inhaled Allergen
Principal Investigator: Erwin W. Gelfand, MD
Source: Environmental Protection Agency - R825702
Amount: $90,000/yr
Term: 1997-2002
Regulation of Mast Cell Cytokine Production
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - RO1 AI 42246
Amount: $169,029/yr
Term: 1998-2003
RSV Enhances Sensitization and Airway Responsiveness
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Gary L. Larsen, MD
Source: National Institutes of Health - RO1 HL61005
Amount: $195,825/yr
Term: 1999-2003
Training Program in Pediatric Immunology
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - T32 A107365
Amount: $133,712/yr
Term: 1990-2005
Collectin-Induced Phagocytosis of Apoptotic Cells
Principal Investigator: Peter Henson, PhD
Co-Investigator: Donna L. Bratton, MD
Source: National Institutes of Health - 1RO1 GM 48211-01
Amount: $220,000/yr
Term: 2001-2005
Neutrophil Apoptosis in Resolution of Inflammation
Principal Investigator: Peter Henson, PhD
Co-Investigator: Donna L. Bratton, MD
Source: National Institutes of Health - 1R01 HL60980
Amount: $209,762/yr
Term: 1998-2002
A Model for Induction of Chronic Fatigue Syndrome
Principal Investigator: James F. Jones, MD
Source: National Institutes of Health - A140990-01A1
Amount: $325,632/yr
Term: 1998-2002
Basic Immune Mechanisms and Immunology Disease
Principal Investigator: John W. Kappler, PhD
Co-Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - T32 AI00048
Amount: $260,987/yr
Term: 1988-2003
Prevention of Chronic Asthma in Young Children (CAPS)
Principal Investigator: Mary D. Klinnert, PhD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Institute of Allergic and Infectious Diseases - R18 AI41137
Term: 1997-2002
General Clinical Research Center
Principal Investigator: Richard D. Krugman, MD
Co-Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health - National Center for Research Resources - 3M01 RR00051
Amount: $8,500,000
Term: 2001-2006
In Vitro Effects of Salmeterol on T-Cell Steroid Responsiveness
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: GlaxoSmithKline
Amount: $67,500
Term: 2001-2002
Pathogenesis and Etiology of Kawasaki Syndrome
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - 5 R01 HL37260-12
Amount: $785,421
Term: 1999-2004
A Phase I/II Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynanucs of Ascending Subcutaneous Doses of HU-901 in Adults with a History of Immediate Hypersensitivity Reaction to Peanut Ingestion
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: Tanox, Inc.
Amount: $360,000
Term: 2000-2002
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety, Efficacy and Pharmacodynamics of HU-901 in Subjects Who Participated in Protocol HU-901.01
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: Tanox, Inc.
Amount: $56,905
Term: 2001-2002
Role of Bacterial Toxins in Human Skin Diseases
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - 5 R01 AR-41256
Amount: $141,000
Term: 2001-2006
A 6-Month, Parallel Group, Randomized, Investigator-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial Comparing the Efficacy of E25 to that of Placebo in the Treatment of Moderate to Severe Atopic Dematitis in Subjects 6-16 Years of Age
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: Novartis Pharmaceuticals Corporation
Amount: $35,552
Term: 2000-2002
A 6-Month, Randomized, Multicenter, Parellel-Group, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of ASM 981 (Pimecrolimus) Cream 1% BID vs. Standard of Care in the Management of Mild to Severe Atopic Dermititis in Adults
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: Novartis Pharmaceuticals Corporation
Amount:$11,079
Term: 2001-2002
Endotoxin and Asthma Prevention in Young Children
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - K23 HL04272
Amount: $123,390
Term: 2001-2006
Immune Pathogenesis and Prevention of Asthma in Young Children
Principal Investigator: Andrew H. Liu, MD
Co-Investigators: Donald Y. M. Leung, MD, PhD, and Mary Klinnert, PhD
Source: National Institutes of Health, General Clinical Research Center - M01 RR00051, NJ137
Term: 1998-2002
Pediatric Asthma and the Home Environment: Provider and Patient Education Project for Medically Indigent Families in Denver, Colorado
Principal Investigators: Andrew H. Liu, MD, and Mark E. Anderson, MD
Source: Environmental Protection Agency, District VIII
Amount: $180,000
Term: 2000-2002
Asthma Clinical Research Network (ACRN)
Principal Investigator: Richard J. Martin, MD
Co-Investigator: Stanley J. Szefler, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - HL 51834
Amount: $600,000/yr
Term: 1998-2003
Immunologic Basis of Environmental Lung Disease
Principal Investigator: Robert J. Mason, MD
Source: Environmental Protection Agency - R825702
Amount: $135,000/yr
Term: 2001-2003
Acute Exposure to Particulate Air Pollution and Childhood Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Environmental Protection Agency - R825702
Amount: $162,289/yr
Term: 2001-2003
Biomarkers of Acute Exposure to Particulate Air Pollution in Childhood Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: National Institutes of Health, General Clinical Research Center - M01 RR00051, NJ160
Amount: $11,513/yr
Term: 1997-2003
SCOR Grant: The Impact of Injury on the Immature Pulmonary Circulation*
Principal Investigator: Kurt R. Stenmark, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - P50 HL 57144
Amount: $7,145,567
Term: 1996-2001
- Project I: SMC Heterogeneity in the Pulmonary Vasculature
Principal Investigator: Kurt R. Stenmark, MD
Amount: $1,324,572
- Project II: Perlecan Heparan Sulfates: Molecular Mechanisms Underlying the Control of Vascular Smooth Muscle Cell Replication and Gene Expression During Normal Development and in Neonatal Pulmonary Hypertension
Principal Investigator: Kurt R. Stenmark, MD
Co-Investigator: Mary C. M. Weiser-Evans, PhD
Amount: $962,228
- Project III: NO-cGMP Cascade in Neonatal Pulmonary Hypertension
Principal Investigator: Steven H. Abman, MD
Co-Investigator: John P. Kinsella, MD
Co-Investigators Clinical Core: John P. Kinsella, MD, and Steven H. Abman, MD
Amount: $1,960,576
- Project IV: Oxidants, Energy and Pulmonary Vascular Development
Principal Investigator: Carl W. White, MD
Amount: $657,184
- Clinical Core
Principal Investigator: Adam A. Rosenberg, MD
Amount: $1,376,432
- Administrative Core
Principal Investigator: Kurt R. Stenmark, MD
Amount: $371,168
Childhood Asthma Management Program (CAMP)
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - N01 HL16048
Amount: $232,098/yr
Term: 1996-2005
Childhood Asthma Management Program (CAMP)
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Joseph D. Spahn, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - N01 HR16048
Amount: $232,098/yr
Term: 1991-2004
Childhood Asthma Research and Education Network (CARE)
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Gary L. Larsen, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - HL64288
Amount: $567,053
Term: 1999-2004
Childhood Asthma Research and Education Network (CARE)
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - HL64288
Amount: $750,000
Term: 2001-2004
Childhood Asthma Research and Education Network (CARE)
Principal Investigator: Stanley J. Szefler, MD
Co-Investigators: Joseph D. Spahn, MD, and Gary L. Larsen, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - HL64288
Amount: $567,053/yr
Term: 2001-2002
Childhood Asthma Research and Education Network (CARE)
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Gary L. Larsen, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - HL64288
Amount: $600,000/yr
Term: 1999-2004
Initiating Inhaled Budesonide in Asthmatic Patients with Recent Onset of Asthma
Principal Investigator: Stanley J. Szefler, MD
Source: Astra, Inc.
Amount: $140,000
Term: 1996-2003
Inner City Asthma Consortium
Principal Investigator: Stanley J. Szefler, MD
Source: National Institutes of Health, National Institutes of Allergy and Infectious Diseases
Amount: $300,000
Term: 2002-2008
Pediatric Pharmacology Research Unit Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Joseph D. Spahn, MD
Source: National Institutes of Health, National Institute of Child Health and Human Development - HD37237
Amount: $1,364,175
Term: 1999-2003
Prevention of Early Asthma in Kids (PEAK)
Principal Investigator: Stanley J. Szefler, MD
Co-Investigators: Joseph D. Spahn, MD, and Gary L. Larsen, MD
Source: National Institutes of Health - UO HL64288A
Amount: $280,276/yr
Term: 2001-2002
Steering Committee, Childhood Asthma Research and Education Network (CARE)
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Lynn M. Taussig, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - 23064403
Amount: $37,250/yr
Term: 1999-2004
Pharmacogenetics Research Network and Database
Principal Investigator: Scott Weiss, MD
Co-Investigator: Erwin W. Gelfand, MD (Denver Site)
Source: National Institutes of Health - 1U01 HL65899-01
Amount: $188,292/yr
Term: 2000-2005
Critical Targets in Hyperoxic Mitochondrial Injury
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - 2 U01 HL56263
Amount: $667,257/yr
Term: 1999-2004
Immunologic Basis of Environmental Lung Disease
Co-Principal Investigator: Carl W. White, MD
Co-Investigator: Robert C. Murphy, PhD
Source: Environmental Protection Agency
Amount: $114,856
Term: 2000-2001
Mechanisms of Ozone Toxicity
Principal Investigator: Carl W. White, MD
Co-Principal Investigator: Robert C. Murphy, PhD
Source: Environmental Protection Agency
Amount: $90,000/yr
Term: 2001-2002
Role of Hexokinase in Lung Absorption to Oxidant Stress
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - 2 R01 HL52732
Amount: $619,792/yr
Term: 1999-2004
1999-2000
Pediatric Asthma and the Home Environment: Provider and Patient Education Project for Medically Indigent Families in Denver, Colorado
Principal Investigators: Mark Anderson, MD, and Andrew H. Liu, MD
Source: Environmental Protection Agency
Amount: $90,000
Term: 2000-2001
Neutrophil Apoptosis in Resolution of Inflammation
Co-Investigator: Donna L. Bratton, MD
Source: National Institutes of Health
Amount: $204,741
Term: 1998-2002
Project II: Inflammation, Airways Reactivity and Asthma
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health
Amount: $202,824
Term: 1996-2001
Regulation of Mast Cell Cytokine Production
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health
Amount: $169,029
Term: 1998-2003
RSV Enhances Sensitization and Airway Responsiveness
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Gary L. Larsen, MD
Source: National Institutes of Health
Amount: $209,517
Term: 1999-2003
Inhalation of Particulate Matter Alters the Allergic Airway Response to Inhaled Allergen
Principal Investigator: Erwin W. Gelfand, MD
Source: Environmental Protection Agency
Amount: $90,000
Term: 1997-2002
Role of T Lymphocytes in Airway Hyperresponsiveness
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Gary L. Larsen, MD
Source: National Institutes of Health
Amount: $208,909
Term: 1991-2001
Ether Lipids, Eicosanoids and Lung Cell Pathophysiology
Principal Investigator: Peter Henson, PhD
Co-Investigator: Donna L. Bratton, MD
Source: National Institutes of Health
Amount: $193,817
Amount: $23,885 (Administrative Core)
Term: 1995-2001
Phosphatidylserine-Specific Removal of Apoptotic Cells
Principal Investigator: Peter Henson, PhD
Co-Investigator: Donna L. Bratton, MD
Source: National Institutes of Health
Amount: $184,153
Term: 1997-2001
A Model for Induction of Chronic Fatigue Syndrome
Principal Investigator: James F. Jones, MD
Source: National Institutes of Health
Amount: $365,745
Term: 1998-2001
Basic Immune Mechanisms and Immunology Disease
Principal Investigator: John Kappler, PhD
Co-Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health
Amount: $260,987
Term: 1988-2003
General Clinical Research Center
Principal Investigator: Richard D. Krugman, MD
Co-Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Center for Research Resources
Amount: $21,510,048
Term: 1996-2001
Project IV of Program Project: Mechanisms of Allergen-Induced Airways Dysfunction
Principal Investigator: Gary L. Larsen, MD
Source: National Institutes of Health
Amount: $201,836
Term: 1996-2001
Administrative Core of Program Project IV
Principal Investigator: Gary L. Larsen, MD
Source: National Institutes of Health
Amount: $84,850
Term: 1996-2001
Inflammation and Airways Reactivity in Asthma
Principal Investigator: Gary L. Larsen, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute
Amount: $1,015,672/yr
Term: 1996-2001
Pathogenesis and Etiology of Kawasaki Syndrome
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Heart, Lung and Blood Institute
Amount: $785,421
Term: 1999-2004
Role of Bacterial Toxins in Human Skin Diseases
Principal Investigator: Donald Y. M. Leung, MD, PhD
Co-Investigator: Mark Boguniewicz, MD
Source: National Institute of Arthritis, Musculoskeletal Skin Diseases
Amount: $705,000
Term: 2000-2005
Immune Pathogenesis and Prevention of Asthma in Young Children
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Division of Research Resources, General Clinical Research Center
Term: 1998-2002
Immune Pathogenesis of Asthma in Young Children
Principal Investigator: Andrew H. Liu, MD
Source: American Academy of Allergy, Asthma and Immunology
Amount: $90,000
Term: 1999-2002
Factors Contributing to Impaired Glucocorticoid Responsiveness in Chronic Asthma
Principal Investigator: Richard Martin, MD
Co-Investigator: Donald Y. M. Leung, MD, PhD
Source: American Lung Association, Asthma Research Center
Amount: $454,545
Term: 1996-2001
Immunologic Basis of Environmental Lung Disease: Effect of Ozone on Mitochondrial and Cellular Function
Co-Principal Investigator: Robert Mason, MD
Co-Investigator: Carl W. White, MD
Source: Environmental Protection Agency
Amount: $107,576
Term: 1999-2001
Oxidant Stress, Energy Impairment, and Inhibition of Lung Growth and Development
Principal Investigator: Kurt R. Stenmark, MD
Co-Investigator: Carl W. White, MD
Source: National Institutes of Health
Amount: $657,184
Term: 1997-2002
Pediatric Asthma Clinical Research Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Joseph D. Spahn, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute
Amount: $600,000
Term: 1999-2000
Initiating Inhaled Budesonide in Asthmatic Patients with Recent Onset of Asthma
Principal Investigator: Stanley J. Szefler, MD
Source: Astra, Inc.
Amount: $140,000
Term: 1996-2003
Childhood Asthma Research and Education Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Gary L. Larsen, MD
Source: National Institutes of Health
Amount: $600,000
Term: 1999-2004
Pediatric Pharmacology Research Unit Network
Principal Investigator: Stanley J. Szefler, MD
Co-Principal Investigators: Mark J. Abzug, MD, and Harley A. Rotbart, MD
Co-Investigator: Joseph D. Spahn, MD
Source: National Institute of Child Health and Human Development
Amount: $1,364,175
Term: 1999-2003
Childhood Asthma Management Program
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Joseph D. Spahn, MD
Source: National Heart, Lung and Blood Institute
Amount: $232,098
Term: 1991-2004
Asthma Clinical Research Network
Co-Principal Investigators: Stanley J. Szefler, MD, and Richard Martin, MD
Source: National Heart, Lung and Blood Institute
Amount: $625,000
Term: 1993-2003
Childhood Asthma Management Program
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Bruce Bender, PhD
Source: National Heart, Lung and Blood Institute
Amount: $178,894
Term: 1999-2000
Pharmacogenetics Research Network and Database
Principal Investigator: Scott Weiss, MD
Co-Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health
Amount: $188,292
Term: 2000-2005
Critical Targets in Hyperoxic Mitochondrial Injury
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health
Amount: $667,257
Term: 1999-2004
Role of Hexokinase in Lung Adaptation to Oxidant Stress
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health
Amount: $619,792
Term: 1999-2004
Oxidant Stress, Energy Impairment, and Inhibition of Lung Growth and Development
Project IV in SCOR Grant: Development of the Pulmonary Circulation: Its Response in Injury
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health
Amount: $121,334/yr
Term: 1997-2002
Mechanisms of Nitrogen Dioxide Toxicity
Co-Principal Investigators: Carl W. White, MD, and Robert C. Murphy, PhD
Source: Environmental Protection Agency
Amount: $110,000
Term: 2000-2001
Immunologic Basis of Environmental Lung Disease
Co-Principal Investigator: Carl W. White, MD
Co-Investigator: Robert C. Murphy, PhD
Source: Environmental Protection Agency
Amount: $114,856
Term: 2000-2001
Glucose-6-Phosphate Dehydrogenase: Role in Oxidant Stress
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health
Amount: $86,642/yr
Term: 1995-1999
Effect of Transgenic Phosphofructokinase Expression on Oxidant Lung Injury
Principal Investigator: Carl W. White, MD
Source: Environmental Protection Agency
Amount: $50,000
Term: February 1998-February 1999
|
|
